Clinical Trial Update: Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease [Phase 1, Phase 2]

View source ↗

Summary

A safety-focused clinical trial update on nebulized BromAc® therapy for COVID-19-related respiratory conditions across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia
• Respiratory Distress Syndrome
• Ventilator-associated Pneumonia

Drugs mentioned

• BromAc

Snippet

Sponsor: Mucpharm Pty Ltd | Conditions: COVID-19 Pneumonia, COVID-19 | Phase 1, Phase 2 | Status: UNKNOWN